SCHEMBL263260

SCHEMBL263260

CCCOc1ccc(F)cc1OBOc1cc(F)ccc1OCCC

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 2/20 0.46
HTR2B P41595 2/20 0.46
HTR2A P28223 1/20 0.46
MAPT P10636 4/20 0.42
HSD17B10 Q99714 1/20 0.42
KDM4E B2RXH2 4/20 0.41
ALDH1A1 P00352 2/20 0.41
MEN1 O00255 1/20 0.41
USP2 O75604 1/20 0.41
TP53 P04637 1/20 0.41
POLB P06746 1/20 0.41
GAA P10253 1/20 0.41
CASP1 P29466 1/20 0.41
HTT P42858 1/20 0.41
CASP7 P55210 1/20 0.41
KMT2A Q03164 1/20 0.41
ATM Q13315 1/20 0.41
L3MBTL1 Q9Y468 5/20 0.40
TDP1 Q9NUW8 2/20 0.40
CYP1A2 P05177 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14237516 0.92 CYP1A2 (0.42) HTR2CHTR2BHTR2AHSD17B10KDM4E
SCHEMBL4018504 0.86 L3MBTL1 (0.46) MAPTKDM4EALDH1A1MEN1GAA
SCHEMBL18688122 0.82 L3MBTL1 (0.54) HTR2CHTR2BHTR2AMAPTHSD17B10
SCHEMBL9632944 0.79 HTR2C (0.46) HTR2CHTR2BHTR2AMAPTHSD17B10
SCHEMBL9633169 0.79 HTR2C (0.49) HTR2CHTR2BHTR2AMAPTHSD17B10
SCHEMBL9633209 0.79 HTR2C (0.52) HTR2CHTR2BHTR2AMAPTHSD17B10
SCHEMBL18688117 0.79 HTR2C (0.46) HTR2CHTR2BHTR2AMAPTHSD17B10
SCHEMBL23188908 0.79 HTR2C (0.48) HTR2CHTR2BHTR2AMAPTHSD17B10
SCHEMBL18688617 0.79 PDE4D (0.50) HTR2CHTR2BHTR2AMAPTHSD17B10
SCHEMBL15986618 0.79 MAPT (0.44) HTR2CHTR2BHTR2AMAPTHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2183241-B1 2-PYRIDINE CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS PFIZER LTD (GB) 2012-12-19 EP disclosed
US-8134007-B2 Pyridine derivatives PFIZER INC. (US) 2012-03-13 US disclosed
EP-2183241-A2 2-PYRIDINE CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS Pfizer Limited (GB) 2010-05-12 EP disclosed
US-20090048306-A1 PYRIDINE DERIVATIVES PFIZER, INC. (US) 2009-02-19 US disclosed
WO-2008135826-A2 2 -PYRIDINE CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS PFIZER LIMITED (GB) 2008-11-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090048306-A1 PYRIDINE DERIVATIVES SDHA, P2RX4, P2RX3 HTR2C 770/4885HTR2B 862/4885HTR2A 1472/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.